Tag: research

New Mexico Senate Committee Unanimously Approves Psilocybin Therapy And Research Resolution

A New Mexico Senate committee has unanimously approved a bipartisan resolution requesting that state officials research the therapeutic potential of psilocybin and explore the creation of a regulatory framework to provide access to the psychedelic.

The Senate Health and Public Affairs Committee voted 7-0 to pass the resolution from Senate Minority Whip Craig Brandt (R) and Sen. Jeff Steinborn (D) on Saturday.

As “memorial” legislation, the bicameral proposal wouldn’t be binding. Rather, it would represent a formal request for the state Department of Health to “study the efficacy of using psilocybin mushrooms for therapeutic treatments and the establishment of a program for psilocybin mushrooms to be used for therapeutic medical treatments.”

The whereas section of the resolution cites various studies supporting the therapeutic benefits of psilocybin for conditions such as major depression and substance misuse, while pointing out that the federal Food and Drug Administration (FDA) has designated the psychedelic as a “breakthrough therapy.”

To that end, the measure states that the health department should look into “necessary statutory or regulatory framework for developing” a state-level psilocybin program.

“This can help people very potentially, and so what we’re trying to do in a bipartisan way is ask the Department of Health to recognize that we want them to get going to start looking at this,” Steinborn said during Saturday’s committee hearing.

The measure “really seeks to expand therapeutic options for New Mexicans,” he said.

Keep reading

Indiana House Panel Approves Psilocybin Research Bill That Already Passed Full Senate

An Indiana House committee has approved a Republican-led bill that would fund clinical research trials into psilocybin that has already cleared the full Senate.

After adopting one amendment, the House Public Health Committee advanced the legislation in a 12-1 vote on Tuesday.

“This is not fringe science at this point, so my original intent was to elevate this potential,” Sen. Ed Charbonneau (R), the bill’s sponsor, told panel members ahead of the vote. “It creates hope for people that currently are in hopeless situations.”

“I think it’s important that we get clear right up front that this bill does not make anything legal that’s illegals today,” he said, highlighting the research-focused nature of the legislation.

Rep. Brad Barrett (R), who chairs the committee, said he was initially “incredibly skeptical” of psilocybin’s therapeutic potential but was moved by testimony he heard during an interim study session on the issue that lawmakers convened last year and “left there with the same kind of feeling” that Charbonneau expressed about the psychedelic’s ability to help people.

Last week, the Senate passed the psychedelics measure in a 47-1 vote. That followed the proposal being passed unanimously by the Senate Appropriations Committee and the Health and Provider Services Committee.

Keep reading

PERCEPTION OF TIME CAN DRAMATICALLY ALTER THIS CRUCIAL BIOLOGICAL PROCESS, NEW STUDY REVEALS

New research from Harvard University shows that a person’s perception of time can directly affect how fast wounds heal.

Previous studies have hinted at a link between the mind and body, particularly in relation to stress and lifestyle. However, this study is the first to show a direct connection between the perception of time and the seemingly autonomous process of healing, opening up the possibility of incorporating time perception into the treatment of injury.

HEALING AND HUMAN PERCEPTION OF TIME

Published in the journal Nature Scientific Reports, the study conducted by Harvard psychologists Peter Aungle and Ellen Langer aimed to determine if the rate of healing was independent of the psychology of the patient or if their perceptions could accelerate or decelerate the healing process.

“Based on the theory of mind–body unity—which posits simultaneous and bidirectional influences of mind on body and body on mind—we hypothesized that wounds would heal faster or slower when perceived time was manipulated to be experienced as longer or shorter respectively,” the researches behind the finding write.

As noted, previous work had found connections between recovery from injury and stress levels, with higher levels of stress potentially interrupting a healthy recovery from injury, but those connections were thought to be primarily physiological in nature.

The researchers also note that previous work studying psychological influences on chronic pain, emotion, and physiological health, and even placebo effects, particularly those involving administration of inert medications, “have led to meaningful improvements in treatments for a broad range of illnesses and injuries.”

Still, this latest study is the first to look at the mindset of the individual, specifically their perception of the passage of time, in relation to recovery rates.

“We hypothesized that experimentally induced wounds would heal faster when more perceived time had passed and heal slower when less perceived time had passed,” the researchers explain, “despite no differences in actual elapsed time.”

Keep reading

DEA Calls For Even More THC, Psilocybin And DMT To Be Produced For Research In 2024

The Drug Enforcement Administration (DEA) is now calling for the production of even more THC, psilocybin and DMT for research purposes than it initially proposed for 2024—raising its quotas for those drugs while maintaining already high production goals for marijuana and other psychedelics.

In a notice set to be published in the Federal Register on Wednesday, DEA said it received comments from registered manufacturers requesting increases to previously proposed 2024 quotas for the Schedule I substances in order to “meet medical and scientific needs,” and it agreed to do so in the new final order.

Accordingly, the agency nearly doubled the quotas for delta-9 THC and all other tetrahydrocannabinol, increasing them to 1,523,040 grams and 1,166,130 grams, respectively.

Keep reading

DEA Renews Push To Ban Two Psychedelics After Abandoning Effort Last Year, Prompting Researchers To Fight Back Again

The Drug Enforcement Administration (DEA) is taking another shot at banning two psychedelics after abandoning its original scheduling proposal last year, teeing up another fight with researchers and advocates who say the compounds hold therapeutic potential.

In a notice published in the Federal Register on Wednesday, DEA again proposed placing 2,5-dimethoxy-4-iodoamphetamine (DOI) and 2,5-dimethoxy-4-chloroamphetamine (DOC) in Schedule I of the Controlled Substances Act (CSA).

The agency said that its scientific and medical basis for proposing the ban “remains the same” as it was last year, so it’s making an identical argument that the phenethylamine hallucinogens hold high abuse potential with no known medical value. What’s changed in the new notice appears to be related to the administrative process of requesting a hearing challenging the facts or laws governing the scheduling action.

When it withdrew its earlier notice, DEA mentioned that it would be “publishing a new proposed rule using an amended procedure.”

DEA doesn’t explain why the amended procedure was necessary, but it is the case that scientists rallied last year to request a hearing on its DOI and DOC scheduling proposal. The psychedelic research company Panacea Plant Sciences had also filed a motion contesting the policy change, which could’ve resulted in an administrative judge scheduling a hearing.

Unlike the previous notice, this latest filing says that the “decision whether a hearing will be needed to address such matters of fact and law in the rulemaking will be made by the Administrator.” There are suspicions that DEA is effectively complicating the process for outside parties to challenge the proposal.

In any case, Panacea Plant Sciences is again sounding the alarm. Founder and CEO David Heldreth told Marijuana Moment on Friday that the “response to our rallying cry to fight the DEA’s illogical rule making has been amazing.”

“The psychedelic community from lawyers and researchers to community activists and even individual people have really come together in opposition to the DEA prohibition mindset,” he said. “Panacea have had contact with at least 10 groups that want to be involved or support the legal fight against the DEA attempt to criminalize DOI and DOC. These compounds are intrinsically important to researchers and the scientific study of the mind and body.”

Keep reading

CONGRESS IS PUSHING REVOLUTIONARY RESEARCH ON PSYCHEDELIC TREATMENTS FOR THE MILITARY

CONGRESS IS ON track to approve legislation that would mark a significant advance in U.S. policy toward psychedelics. 

Tucked into the National Defense Authorization Act of 2024 is a provision to fund clinical trials using psychedelic substances to treat active duty members of the military.

Section 723 of the NDAA directs the secretary of defense to partner with a federal or state government agency, or an academic institution, to carry out the research. The bill would fund the treatment of members of the military with post-traumatic stress or a traumatic brain injury with a number of psychedelic substances, including MDMA, psilocybin, ibogaine, DMT, and other plant-based alternative therapies (such as ayahuasca).

Research surrounding psychedelics as a possible treatment for post-traumatic stress disorder have slowly grown, and recent studies have shown promising results, with patients benefiting from even just a few treatments including MDMA and psilocybin. Already, the Food and Drug Administration has designated both treatments as “breakthrough therapies”: a special designation given to expedite the research and development into drugs with the potential to treat serious conditions. On Tuesday, MAPS Public Benefit Corporation, which focuses on psychedelic treatments for mental health issues, submitted a new drug application to the FDA for MDMA-assisted therapy for PTSD. The company says it’s the first such submission for any psychedelic-assisted therapy.

Keep reading

Colorado Governor Says Marijuana Prohibition Created A ‘Chicken And The Egg’ Research Dilemma That’s Blocked Federal Reform

The governor of Colorado says that while marijuana reform is “not really a partisan issue” anymore, there are still “stodgy nanny state Republicans who want to control it.” Meanwhile, he says, ongoing prohibition has inhibited research into the science of cannabis that’s kept it strictly criminalized at the federal level.

Gov. Jared Polis (D) is hoping that will change sooner rather than later. He and the governors of five other states sent a letter to President Joe Biden this week, urging officials to reschedule marijuana under the Controlled Substances Act (CSA) by the end of the year.

In an interview that aired on Fox News Radio’s “The Guy Benson Show” on Thursday, Polis said he would’ve liked to see a federal policy change five or 10 years ago as states such as Colorado enacted adult-use legalization, but he theorized that prohibition itself created a “chicken and the egg” situation that has effectively stymied reform by making it harder to conduct research on the effects of cannabis, a stalemate that has been reinforced by congressional politics.

The administrative marijuana scheduling review that Biden directed last year could help break that policy logjam, he said. The U.S. Department of Health and Human Services (HHS) has already determined that cannabis should be moved from Schedule I t0 Schedule III, and now it’s up to the Drug Enforcement Administration (DEA) to make a final determination.

Keep reading

Top Federal Agency Promotes New Marijuana Research Center Amid Scientists’ Complaints About ‘Complex’ Study ‘Barriers’ Under Prohibition

A top federal health agency says it recognizes that there are ample concerns among scientists about how they’ve “encountered barriers that have hampered their research” into marijuana under federal prohibition, including “complex” federal regulations and inadequate supplies of cannabis.

That’s why the National Institutes of Health (NIH) is now seeking to resolve some of those challenges by standing up a Resource Center for Cannabis and Cannabinoid Research, an official said in a blog post on Tuesday.

NIH posted a notice of funding opportunity late last month, explaining how it’s seeking an entity to operate the center through a cooperative agreement in order to “address challenges and barriers to conducting research on cannabis and its constituents.”

To help facilitate that process, the National Center for Complementary and Integrative Health’s (NCCIH) Patrick Still announced that the health agency will be holding a webinar on January 25 to provide potential applicants with technical assistance.

“There’s growing interest in potential therapeutic uses of cannabis and its constituents among both health care providers and the public,” Still, who is a program director for NCCIH’s Basic and Mechanistic Research branch, wrote. “Substances in cannabis have a variety of pharmacologic effects, and rigorous research is needed to understand their mechanisms of action and investigate their possible value in helping to manage health conditions.”

“However, investigators working in this field have encountered barriers that have hampered their research,” he said, pointing to feedback NCCIH received as part of a request for information last year.

“The barriers that many of them have mentioned include difficulty meeting complex federal and state regulatory requirements, problems obtaining cannabis products suitable for research, a lack of validated measures of cannabis use and exposure, and inadequate scientific infrastructure to support research studies,” Still wrote.

Keep reading

Ibram Kendi’s Center for Antiracist Research Hasn’t Produced Any Research

Ibram X. Kendi’s Center for Antiracist Research made headlines this month when it announced it would axe a third of its workforce. But those layoffs may not have much of an impact, considering the center has hardly produced any original research at all.

The Boston University-based center has produced just two original research papers since its founding in June 2020, according to a Washington Free Beacon review. Output from the center’s scholars largely consists of op-eds or commentary posted on the center’s website. The group’s plans to “maintain the nation’s largest online database of racial inequity data in the United States” quickly fizzled out, and the database has been dormant since 2021.

The Center for Antiracist Research is the latest left-wing group to fall on hard times. George Soros’s Open Society Foundations, which gave $140,000 to Kendi’s center, cut 40 percent of its staff in June. The Black Lives Matter Global Network Foundation’s revenues fell 88 percent from 2021 to 2022, as support for the movement plummeted to an all-time low.

It is unclear how much money remains in the Center for Antiracist Research’s coffers. Boston University did not respond to a request for comment.

Kendi had high hopes for the center, which employed at least 45 employees as of July. The nonprofit would “foster exhaustive racial research, research-based policy innovation, data-driven education and advocacy campaigns, and narrative-change initiatives,” Kendi said, in order to “figure out novel and practical ways to understand, explain, and solve seemingly tractable problems of racial inequity and injustice.”

In December 2020, the center launched the “Racial Data Lab,” which Kendi claimed would “give us the ability to see the hotspots of racial inequity in real time in this country.” As of September, the Racial Data Lab only compiled information on COVID-19 infections and deaths. That COVID-19 tracker stopped collecting information in March 2021. The center has since removed the names of anyone who worked on that project from its website.

The center’s scholars have produced only two research papers, both of which were co-authored with a number of other academics. Elaine Nsoesie, who leads the Racial Data Tracker project at the center, appeared last in a list of co-authors of the January paper “Association of Neighborhood Racial and Ethnic Composition and Historical Redlining With Build Environment Indicators Derived From Street View Images.”

Nsoesie’s low ranking among her co-authors could suggest she contributed the least to the paper, which concluded that neighborhoods with a higher concentration of black residents had more “dilapidated buildings.”

Keep reading

Ohio State receives first-ever DEA license to grow psychedelic mushrooms for research

Ohio State University is about to grow psychedelic mushrooms.

For scientific research, people.

Ohio State, alongside the mental health and wellness research and development company Inner State Inc., was awarded the first-ever license by the U.S. Drug Enforcement Agency to grow whole psilocybin mushrooms. The mushrooms will be used in the study of mental health treatment capabilities with naturally grown psychedelic mushrooms.

“This license is a major milestone not only for Inner State and Ohio State, but for the entire field of psychedelic research,” Inner State CEO Ashley Walsh said Wednesday in a news release.

The license allows Ohio State and Inner State to cultivate psilocybin mushrooms for research purposes only. All research will be conducted in a federally sanctioned and secured grow house in accordance with strict DEA regulations and guidelines.

“By combining cutting-edge techniques in genomics and metabolomics, we have the opportunity to obtain a high-resolution picture of the chemical diversity of mushrooms that have remained difficult to study for several decades,” according to Ohio State researchers Dr. Jason Slot and Dr. Kou-San Ju.

Keep reading